Marvel Biosciences Announces an Amendment to the Conversion Price for Marvel’s Proposed Convertible Debenture Offering
Calgary, Alberta – April 13, 2026 - Marvel Biosciences Corp. (TSXV: MRVL) (“Marvel” or the “Company”) Further tothe Company’s press release of April 8, 2026, announcing its intention to complete a non-brokered private placementoffering of unsecured convertible debentures (“Debentures”) in the principal amount of up to $500,000 (the “Offering”),Marvel wishes to announce that it has amended the...
Marvel Biosciences Announces Proposed Convertible Debenture Offering
Calgary, Alberta – April 8, 2026 - Marvel Biosciences Corp. (TSXV: MRVL) (“Marvel” or the “Company”) announced today its intention to complete a non-brokered private placement offering of unsecured convertible debentures (“Debentures”) in the principal amount of up to $500,000 (the “Offering”), subject to final approval of the TSX Venture Exchange. The Debentures will bear interest at the rate...
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
Calgary, Alberta – April 7, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions, today announces that is has secured financial and strategic support from 5 Horizons Ventures for the...
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
Calgary, Alberta – March 30, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum disorder and related conditions, today announced it has secured non-dilutive funding from the Alberta Innovates' Accelerating...
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
Calgary, Alberta – March 25, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that it has selected Novotech as the contract research organization (“CRO”)...
Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
Calgary, Alberta – March 18, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions, is pleased to announce that the US Patent Office has issued Patent No. 12,570,656 B2 for MB-204...
Marvel Biosciences Sponsors Scientific Meeting on Purines
Calgary, Alberta – March 4, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a biotechnology company developing novel therapies for neurological and neurodevelopmental disorders, today announced it is sponsoring the 3rd European Purine Meeting taking place in Bordeaux, France, from June...
Marvel Biosciences Announces Grant of Deferred Share Units
Calgary, Alberta, Canada - Wednesday, February 18, 2026 - Marvel Biosciences Corp. (TSX-V: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), announces the award of 50,001 deferred share units (“DSUs”) to Marvel’s three independent directors, in lieu of cash payment for directors’ fees. The DSUs will all vest on February 17, 2027. Vested...
Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders
Calgary, Alberta – Wednesday, February 18, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), is pleased to announce that it is receiving advisory services and funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support research and development of a pediatric-friendly liquid formulation of its lead compound, MB-204. The NRC...
Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
Calgary, Alberta – February 3, 2026 – Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel therapeutics for autism spectrum disorder and related neurological conditions, is pleased to announce that the Japan Patent Office has granted Japanese Patent No....